Type of ANCA May Be Indispensable in Distinguishing Subphenotypes of Different Clinical Entities in ANCA-Associated Vasculitis

• Published in: Life (Basel, Switzerland) Switzerland), 2022-09, Vol.12 (10), p.1467
• Main Authors: Konstantouli, Afroditi Maria, Lioulios, Georgios, Stai, Stamatia, Moysidou, Eleni, Fylaktou, Asimina, Papagianni, Aikaterini, Stangou, Maria
• Format: Article
• Language: English
• Subjects: ANCA-associated vasculitis; Antibodies; Antigens; Antineutrophil cytoplasmic antibodies; Classification; clinical phenotype; Clinical trials; Cytokines; Epidemiology; Gender; Granulomatosis; Immune system; Leukocytes (eosinophilic); myeloperoxidase; Neutrophils; Nomenclature; outcome; Pathogenesis; Phenotypes; proteinase 3; Review; Ultraviolet radiation; Vasculitis
• ISSN: 2075-1729; 2075-1729
• DOI: 10.3390/life12101467

The traditional nomenclature system for classifying antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) based on clinical phenotype describes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and microscopic polyangiitis (MPA) as distinct clinical entities. This classification has proved its expedience in clinical trials and everyday clinical practice; yet, a substantial overlap in clinical presentation still exists and often causes difficulties in prompt definition and clinical distinction. Additionally, new insights into the AAV pathogenesis point out that PR3 and MPO-AAV may not represent expressions of the same disease spectrum but rather two distinct disorders, as they display significant differences. Thus, it is supported that a classification based on ANCA serotype (PR3-ANCA, MPO-ANCA or ANCA-negative) could be more accurate and also closer to the nature of the disease compared to the phenotype-based one. This review aims to elucidate the major differences between PR3 and MPO-AAV in terms of epidemiology, pathogenesis, histological and clinical manifestations and response to therapeutic approaches.